TD Cowen cuts MDxHealth stock price target on Medicare dispute By Investing.com

TD Cowen cut MDxHealth’s price target to $1.50 from $7.00 while keeping a Buy rating, but the revision reflects weaker fundamentals and compressed valuation multiples. Q1 pro forma sales came in about 9% below consensus, Q1 2026 EPS was -$0.17 versus -$0.15 expected, and revenue of $27.4 million missed the $31.12 million estimate. The company is also discontinuing its Resolve UTI test, which accounted for roughly 16% of sales, amid a $10.4 million Medicare recoupment dispute and reduced guidance.

Analysis

This is less a clean valuation reset than a forced de-rating caused by a collapsed revenue base and a credibility hit. When a diagnostics company removes a product that was still growing faster than the core and contributed a meaningful slice of sales, the market usually starts pricing a smaller TAM plus lower operating leverage, not just a one-time earnings haircut. The key second-order effect is that any lingering fixed-cost absorption problem can keep gross margin looking acceptable while EBITDA and cash burn deteriorate faster than consensus models imply.

The legal/regulatory overhang matters more than the revenue loss because it creates a multi-quarter cloud over reimbursement assumptions for the broader menu, not just the discontinued test. Even if the company ultimately wins part of the dispute, the process itself can freeze commercial momentum as sales teams and payors wait for clarity. In small-cap diagnostics, that often leads to a longer period of multiple compression than the fundamentals alone would justify, because investors demand proof of stable collections before rerating the equity.

The contrarian angle is that this may already be pricing a highly punitive scenario: the stock is trading as if the business has limited optionality and no recovery path, which can be too low if management can stabilize the remaining franchise and avoid further reimbursement shocks. But the asymmetry still favors caution because the next catalyst is likely another data point on shrinking top line or weak cash conversion, while any positive resolution on the dispute is timing-uncertain. For a trading horizon of 1-3 months, the path of least resistance is lower unless the company provides explicit evidence that the post-exit base can sustain margins and reduce burn.

Key Decisions for Investors

• Avoid initiating a new long in MDXH ahead of the next print; the risk/reward is poor until there is evidence of post-exit revenue stabilization and collections normalization.
• For existing holders, reduce exposure on strength and treat rallies as de-risking opportunities over the next 2-6 weeks; this is a balance-sheet-and-reimbursement story, not a quick multiple recovery.
• If seeking a tactical expression, consider a small short or put spread in MDXH into any rebound tied to litigation optimism; target a 1-3 month window with defined premium at risk.
• Pair trade: long higher-quality diagnostics names with recurring reimbursement visibility versus short MDXH, to isolate the downside from company-specific reimbursement and execution risk.
• Set a catalyst watchlist around any MAC dispute update or revised guidance; only a materially favorable resolution paired with stable sequential revenue would justify revisiting the long case.